85,000 Caris Life Sciences, Inc. $CAI Shares Sold by Salem Investment Counselors Inc.

Salem Investment Counselors Inc. trimmed its holdings in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) by 85.0% in the third quarter, Holdings Channel reports. The institutional investor owned 15,000 shares of the company’s stock after selling 85,000 shares during the period. Salem Investment Counselors Inc.’s holdings in Caris Life Sciences were worth $459,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in CAI. GAMMA Investing LLC increased its holdings in shares of Caris Life Sciences by 133.0% in the 3rd quarter. GAMMA Investing LLC now owns 1,263 shares of the company’s stock valued at $39,000 after acquiring an additional 721 shares during the last quarter. Sterling Capital Management LLC raised its position in shares of Caris Life Sciences by 128.3% during the 1st quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock worth $34,000 after acquiring an additional 1,083 shares in the last quarter. PNC Financial Services Group Inc. raised its position in shares of Caris Life Sciences by 839.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock worth $29,000 after acquiring an additional 1,469 shares in the last quarter. PEAK6 LLC lifted its stake in Caris Life Sciences by 6.9% during the fourth quarter. PEAK6 LLC now owns 24,800 shares of the company’s stock worth $669,000 after purchasing an additional 1,600 shares during the last quarter. Finally, Strs Ohio lifted its stake in Caris Life Sciences by 301.3% during the first quarter. Strs Ohio now owns 2,179 shares of the company’s stock worth $39,000 after purchasing an additional 1,636 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on CAI shares. Wall Street Zen raised Caris Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. TD Cowen increased their price target on shares of Caris Life Sciences from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday. Evercore reissued an “outperform” rating and set a $26.00 price objective on shares of Caris Life Sciences in a report on Thursday, August 6th. BTIG Research boosted their price objective on shares of Caris Life Sciences from $32.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Caris Life Sciences from $25.00 to $35.00 and gave the stock an “overweight” rating in a research report on Wednesday. Eight investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.82.

Insider Transactions at Caris Life Sciences

In other news, President David Spetzler sold 119,212 shares of Caris Life Sciences stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $24.76, for a total transaction of $2,951,689.12. Following the sale, the president owned 1,182,871 shares in the company, valued at approximately $29,287,885.96. The trade was a 9.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Brian Brille sold 400,000 shares of the business’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $30.33, for a total value of $12,132,000.00. Following the completion of the sale, the insider directly owned 230,303 shares of the company’s stock, valued at $6,985,089.99. The trade was a 63.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 1,004,712 shares of company stock worth $27,205,419. Corporate insiders own 50.00% of the company’s stock.

Caris Life Sciences Stock Performance

NASDAQ CAI opened at $30.25 on Thursday. The company has a debt-to-equity ratio of 0.66, a current ratio of 5.53 and a quick ratio of 4.88. Caris Life Sciences, Inc. has a 1 year low of $14.19 and a 1 year high of $33.65. The company has a market capitalization of $8.55 billion, a PE ratio of 82.03 and a beta of 0.86. The company has a fifty day moving average of $26.73 and a two-hundred day moving average of $20.75.

Caris Life Sciences Company Profile

Caris Life Sciences is a biotechnology company focused on precision oncology and the use of molecular and artificial intelligence technologies to support cancer diagnosis and treatment decisions. The company analyzes tumor and blood samples to identify genetic, molecular and other biological characteristics that may help physicians select targeted therapies and develop individualized treatment plans.

Its offerings include comprehensive tumor profiling, molecular testing and data-driven clinical support for oncologists and other healthcare providers.